Kura Oncology Inc. held a presentation focusing on their investigational menin inhibitor, Ziftomenib, targeted at treating relapsed/refractory and newly diagnosed acute myeloid leukemia $(AML.AU)$. The presentation highlighted the positive results from the Phase 2 KOMET-001 trial, which led to a New Drug Application (NDA) for Ziftomenib. This NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025. The presentation also discussed the Ziftomenib Global Development Plan, including the KOMET-017 Phase 3 clinical trials and the market opportunity for newly diagnosed NPM1-m and KMT2A-r AML patients. Key opinion leaders such as Dr. Harry Erba and Dr. Ghayas C. Issa participated in the event. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.